Kintara Therapeutics (KTRA) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Kintara Therapeutics is urging stockholders to vote on a pivotal merger with TuHURA Biosciences, aiming to combine resources for advancing cancer therapies. The all-stock transaction, subject to stockholder approval, would result in Kintara equity holders owning a minority stake in the new entity, which will be named TuHURA Biosciences and trade under the ticker ‘HURA’. The merger, contingent on traditional closing conditions, is slated for completion in the third quarter of 2024.
For further insights into KTRA stock, check out TipRanks’ Stock Analysis page.
